URMC Research Network

Find People
Keyword
Last Name
 
More Search Options

Shreedevi Pandya

TitleAssistant Professor (Svc) (Part-Time)
InstitutionSchool of Medicine and Dentistry
DepartmentNeurology
AddressUniversity of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 673
Rochester NY 14642
 
 Awards And Honors
1969     Outstanding Physiotherapist, Class of 1969 Bombay Branch, Indian Association of Physiotherapy
2004     Research Award, Pediatric Section, American Physical Therapy Association
 
 Selected Publications
List All   |   Timeline
  1. Pettygrove S, Lu Z, Andrews JG, Meaney FJ, Sheehan DW, Price ET, Fox DJ, Pandya S, Ouyang L, Apkon SD, Powis Z, Cunniff C. Sibling concordance for clinical features of Duchenne and Becker muscular dystrophies. Muscle Nerve. 2014 Jun; 49(6):814-21.
    View in: PubMed
  2. Nakamori M, Sobczak K, Puwanant A, Welle S, Eichinger K, Pandya S, Dekdebrun J, Heatwole CR, McDermott MP, Chen T, Cline M, Tawil R, Osborne RJ, Wheeler TM, Swanson MS, Moxley RT, Thornton CA. Splicing biomarkers of disease severity in myotonic dystrophy. Ann Neurol. 2013 Dec; 74(6):862-72.
    View in: PubMed
  3. Cano SJ, Mayhew A, Glanzman AM, Krosschell KJ, Swoboda KJ, Main M, Steffensen BF, Bérard C, Girardot F, Payan CA, Mercuri E, Mazzone E, Elsheikh B, Florence J, Hynan LS, Iannaccone ST, Nelson LL, Pandya S, Rose M, Scott C, Sadjadi R, Yore MA, Joyce C, Kissel JT. Rasch analysis of clinical outcome measures in spinal muscular atrophy. Muscle Nerve. 2014 Mar; 49(3):422-30.
    View in: PubMed
  4. Barber BJ, Andrews JG, Lu Z, West NA, Meaney FJ, Price ET, Gray A, Sheehan DW, Pandya S, Yang M, Cunniff C. Oral corticosteroids and onset of cardiomyopathy in duchenne muscular dystrophy. J Pediatr. 2013 Oct; 163(4):1080-1084.e1.
    View in: PubMed
  5. Griggs RC, Herr BE, Reha A, Elfring G, Atkinson L, Cwik V, McColl E, Tawil R, Pandya S, McDermott MP, Bushby K. Corticosteroids in Duchenne muscular dystrophy: Major variations in practice. Muscle Nerve. 2013 Jul; 48(1):27-31.
    View in: PubMed
  6. Statland JM, McDermott MP, Heatwole C, Martens WB, Pandya S, van der Kooi EL, Kissel JT, Wagner KR, Tawil R. Reevaluating measures of disease progression in facioscapulohumeral muscular dystrophy. Neuromuscul Disord. 2013 Apr; 23(4):306-12.
    View in: PubMed
  7. Statland JM, Bundy BN, Wang Y, Trivedi JR, Raja Rayan D, Herbelin L, Donlan M, McLin R, Eichinger KJ, Findlater K, Dewar L, Pandya S, Martens WB, Venance SL, Matthews E, Amato AA, Hanna MG, Griggs RC, Barohn RJ. A quantitative measure of handgrip myotonia in non-dystrophic myotonia. Muscle Nerve. 2012 Oct; 46(4):482-9.
    View in: PubMed
  8. Rose MR, Sadjadi R, Weinman J, Akhtar T, Pandya S, Kissel JT, Jackson CE. Role of disease severity, illness perceptions, and mood on quality of life in muscle disease. Muscle Nerve. 2012 Sep; 46(3):351-9.
    View in: PubMed
  9. Sadjadi R, Vincent KA, Carr AJ, Walburn J, Brooks VL, Pandya S, Kissel JT, Jackson CE, Rose MR. Validation of the individualised neuromuscular quality of life for the USA with comparison of the impact of muscle disease on those living in USA versus UK. Health Qual Life Outcomes. 2011; 9:114.
    View in: PubMed
  10. Nabukera SK, Romitti PA, Campbell KA, Meaney FJ, Caspers KM, Mathews KD, Sherlock SM, Puzhankara S, Cunniff C, Druschel CM, Pandya S, Matthews DJ, Ciafaloni E. Use of complementary and alternative medicine by males with Duchenne or Becker muscular dystrophy. J Child Neurol. 2012 Jun; 27(6):734-40.
    View in: PubMed
  11. Holtzer C, Meaney FJ, Andrews J, Ciafaloni E, Fox DJ, James KA, Lu Z, Miller L, Pandya S, Ouyang L, Cunniff C. Disparities in the diagnostic process of Duchenne and Becker muscular dystrophy. Genet Med. 2011 Nov; 13(11):942-7.
    View in: PubMed
  12. Moxley RT, Pandya S. Weekend high-dosage prednisone: a new option for treatment of Duchenne muscular dystrophy. Neurology. 2011 Aug 2; 77(5):416-7.
    View in: PubMed
  13. Statland JM, Wang Y, Richesson R, Bundy B, Herbelin L, Gomes J, Trivedi J, Venance S, Amato A, Hanna M, Griggs R, Barohn RJ. An interactive voice response diary for patients with non-dystrophic myotonia. Muscle Nerve. 2011 Jul; 44(1):30-5.
    View in: PubMed
  14. Arias R, Andrews J, Pandya S, Pettit K, Trout C, Apkon S, Karwoski J, Cunniff C, Matthews D, Miller T, Davis MF, Meaney FJ. Palliative care services in families of males with Duchenne muscular dystrophy. Muscle Nerve. 2011 Jul; 44(1):93-101.
    View in: PubMed
  15. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol. 2011 Sep; 70(3):427-36.
    View in: PubMed
  16. Heatwole CR, Eichinger KJ, Friedman DI, Hilbert JE, Jackson CE, Logigian EL, Martens WB, McDermott MP, Pandya SK, Quinn C, Smirnow AM, Thornton CA, Moxley RT. Open-label trial of recombinant human insulin-like growth factor 1/recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1. Arch Neurol. 2011 Jan; 68(1):37-44.
    View in: PubMed
  17. Sadjadi R, Rose MR. What determines quality of life in inclusion body myositis? J Neurol Neurosurg Psychiatry. 2010 Oct; 81(10):1164-6.
    View in: PubMed
  18. Moxley RT, Pandya S, Ciafaloni E, Fox DJ, Campbell K. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol. 2010 Sep; 25(9):1116-29.
    View in: PubMed
  19. Matthews DJ, James KA, Miller LA, Pandya S, Campbell KA, Ciafaloni E, Mathews KD, Miller TM, Cunniff C, Meaney FJ, Druschel CM, Romitti PA, Fox DJ. Use of corticosteroids in a population-based cohort of boys with duchenne and becker muscular dystrophy. J Child Neurol. 2010 Nov; 25(11):1319-24.
    View in: PubMed
  20. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010 Feb; 9(2):177-89.
    View in: PubMed
  21. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010 Jan; 9(1):77-93.
    View in: PubMed
  22. Montes J, Gordon AM, Pandya S, De Vivo DC, Kaufmann P. Clinical outcome measures in spinal muscular atrophy. J Child Neurol. 2009 Aug; 24(8):968-78.
    View in: PubMed
  23. Ciafaloni E, Fox DJ, Pandya S, Westfield CP, Puzhankara S, Romitti PA, Mathews KD, Miller TM, Matthews DJ, Miller LA, Cunniff C, Druschel CM, Moxley RT. Delayed diagnosis in duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). J Pediatr. 2009 Sep; 155(3):380-5.
    View in: PubMed
  24. Cunniff C, Andrews J, Meaney FJ, Mathews KD, Matthews D, Ciafaloni E, Miller TM, Bodensteiner JB, Miller LA, James KA, Druschel CM, Romitti PA, Pandya S. Mutation analysis in a population-based cohort of boys with Duchenne or Becker muscular dystrophy. J Child Neurol. 2009 Apr; 24(4):425-30.
    View in: PubMed
  25. Wagner KR, Fleckenstein JL, Amato AA, Barohn RJ, Bushby K, Escolar DM, Flanigan KM, Pestronk A, Tawil R, Wolfe GI, Eagle M, Florence JM, King WM, Pandya S, Straub V, Juneau P, Meyers K, Csimma C, Araujo T, Allen R, Parsons SA, Wozney JM, Lavallie ER, Mendell JR. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol. 2008 May; 63(5):561-71.
    View in: PubMed
  26. Jackson CE, Barohn RJ, Gronseth G, Pandya S, Herbelin L. Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity. Muscle Nerve. 2008 Apr; 37(4):473-6.
    View in: PubMed
  27. Pandya S, King WM, Tawil R. Facioscapulohumeral dystrophy. Phys Ther. 2008 Jan; 88(1):105-13.
    View in: PubMed
  28. Moxley RT, Logigian EL, Martens WB, Annis CL, Pandya S, Moxley RT, Barbieri CA, Dilek N, Wiegner AW, Thornton CA. Computerized hand grip myometry reliably measures myotonia and muscle strength in myotonic dystrophy (DM1). Muscle Nerve. 2007 Sep; 36(3):320-8.
    View in: PubMed
  29. Logigian EL, Ciafaloni E, Quinn LC, Dilek N, Pandya S, Moxley RT, Thornton CA. Severity, type, and distribution of myotonic discharges are different in type 1 and type 2 myotonic dystrophy. Muscle Nerve. 2007 Apr; 35(4):479-85.
    View in: PubMed
  30. Miller LA, Romitti PA, Cunniff C, Druschel C, Mathews KD, Meaney FJ, Matthews D, Kantamneni J, Feng ZF, Zemblidge N, Miller TM, Andrews J, Fox D, Ciafaloni E, Pandya S, Montgomery A, Kenneson A. The muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet): surveillance methodology. Birth Defects Res A Clin Mol Teratol. 2006 Nov; 76(11):793-7.
    View in: PubMed
  31. Moore SA, Shilling CJ, Westra S, Wall C, Wicklund MP, Stolle C, Brown CA, Michele DE, Piccolo F, Winder TL, Stence A, Barresi R, King N, King W, Florence J, Campbell KP, Fenichel GM, Stedman HH, Kissel JT, Griggs RC, Pandya S, Mathews KD, Pestronk A, Serrano C, Darvish D, Mendell JR. Limb-girdle muscular dystrophy in the United States. J Neuropathol Exp Neurol. 2006 Oct; 65(10):995-1003.
    View in: PubMed
  32. Moxley RT, Ashwal S, Pandya S, Connolly A, Florence J, Mathews K, Baumbach L, McDonald C, Sussman M, Wade C. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2005 Jan 11; 64(1):13-20.
    View in: PubMed
  33. Bodhe PV, Kotwani RN, Kirodian BG, Kshirsagar NA, Pandya SK. Open label, randomised, comparative phase III safety and efficacy study with conventional amphotericin B and liposomal amphotericin B in patients with systemic fungal infection. J Assoc Physicians India. 2002 May; 50(5):662-70.
    View in: PubMed
  34. Kissel JT, McDermott MP, Mendell JR, King WM, Pandya S, Griggs RC, Tawil R. Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy. Neurology. 2001 Oct 23; 57(8):1434-40.
    View in: PubMed
  35. Pandya S, Boris-Lawrie K, Leung NJ, Akkina R, Planelles V. Development of an Rev-independent, minimal simian immunodeficiency virus-derived vector system. Hum Gene Ther. 2001 May 1; 12(7):847-57.
    View in: PubMed
  36. Fenichel GM, Griggs RC, Kissel J, Kramer TI, Mendell JR, Moxley RT, Pestronk A, Sheng K, Florence J, King WM, Pandya S, Robison VD, Wang H. A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy. Neurology. 2001 Apr 24; 56(8):1075-9.
    View in: PubMed
  37. Pandya S, Klimatcheva E, Planelles V. Lentivirus and foamy virus vectors: novel gene therapy tools. Expert Opin Biol Ther. 2001 Jan; 1(1):17-40.
    View in: PubMed
  38. Schwid SR, Thornton CA, Pandya S, Manzur KL, Sanjak M, Petrie MD, McDermott MP, Goodman AD. Quantitative assessment of motor fatigue and strength in MS. Neurology. 1999 Sep 11; 53(4):743-50.
    View in: PubMed
  39. White SM, Renda M, Nam NY, Klimatcheva E, Zhu Y, Fisk J, Halterman M, Rimel BJ, Federoff H, Pandya S, Rosenblatt JD, Planelles V. Lentivirus vectors using human and simian immunodeficiency virus elements. J Virol. 1999 Apr; 73(4):2832-40.
    View in: PubMed
  40. Kissel JT, McDermott MP, Natarajan R, Mendell JR, Pandya S, King WM, Griggs RC, Tawil R. Pilot trial of albuterol in facioscapulohumeral muscular dystrophy. FSH-DY Group. Neurology. 1998 May; 50(5):1402-6.
    View in: PubMed
  41. Tawil R, McDermott MP, Pandya S, King W, Kissel J, Mendell JR, Griggs RC. A pilot trial of prednisone in facioscapulohumeral muscular dystrophy. FSH-DY Group. Neurology. 1997 Jan; 48(1):46-9.
    View in: PubMed
  42. A prospective, quantitative study of the natural history of facioscapulohumeral muscular dystrophy (FSHD): implications for therapeutic trials. The FSH-DY Group. Neurology. 1997 Jan; 48(1):38-46.
    View in: PubMed
  43. Tawil R, Forrester J, Griggs RC, Mendell J, Kissel J, McDermott M, King W, Weiffenbach B, Figlewicz D. Evidence for anticipation and association of deletion size with severity in facioscapulohumeral muscular dystrophy. The FSH-DY Group. Ann Neurol. 1996 Jun; 39(6):744-8.
    View in: PubMed
  44. Tawil R, McDermott MP, Mendell JR, Kissel J, Griggs RC. Facioscapulohumeral muscular dystrophy (FSHD): design of natural history study and results of baseline testing. FSH-DY Group. Neurology. 1994 Mar; 44(3 Pt 1):442-6.
    View in: PubMed
  45. Personius KE, Pandya S, King WM, Tawil R, McDermott MP. Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. The FSH DY Group. Phys Ther. 1994 Mar; 74(3):253-63.
    View in: PubMed
  46. Griggs RC, Moxley RT, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, Miller JP, Cwik VA, Pandya S, Robison J, et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months) Neurology. 1993 Mar; 43(3 Pt 1):520-7.
    View in: PubMed
  47. Florence JM, Pandya S, King WM, Robison JD, Baty J, Miller JP, Schierbecker J, Signore LC. Intrarater reliability of manual muscle test (Medical Research Council scale) grades in Duchenne's muscular dystrophy. Phys Ther. 1992 Feb; 72(2):115-22; discussion 122-6.
    View in: PubMed
  48. Fenichel GM, Florence JM, Pestronk A, Mendell JR, Moxley RT, Griggs RC, Brooke MH, Miller JP, Robison J, King W, et al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology. 1991 Dec; 41(12):1874-7.
    View in: PubMed
  49. Fenichel GM, Mendell JR, Moxley RT, Griggs RC, Brooke MH, Miller JP, Pestronk A, Robison J, King W, Signore L, et al. A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. Arch Neurol. 1991 Jun; 48(6):575-9.
    View in: PubMed
  50. Griggs RC, Moxley RT, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, Miller JP. Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Arch Neurol. 1991 Apr; 48(4):383-8.
    View in: PubMed
  51. Mendell JR, Moxley RT, Griggs RC, Brooke MH, Fenichel GM, Miller JP, King W, Signore L, Pandya S, Florence J, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med. 1989 Jun 15; 320(24):1592-7.
    View in: PubMed
  52. Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley R, Florence J, King WM, Pandya S, Robison J, Schierbecker J, et al. Duchenne muscular dystrophy: patterns of clinical progression and effects of supportive therapy. Neurology. 1989 Apr; 39(4):475-81.
    View in: PubMed
  53. Griggs RC, Pandya S, Florence JM, Brooke MH, Kingston W, Miller JP, Chutkow J, Herr BE, Moxley RT. Randomized controlled trial of testosterone in myotonic dystrophy. Neurology. 1989 Feb; 39(2 Pt 1):219-22.
    View in: PubMed
  54. Fenichel GM, Brooke MH, Griggs RC, Mendell JR, Miller JP, Moxley RT, Park JH, Provine MA, Florence J, Kaiser KK, et al. Clinical investigation in Duchenne muscular dystrophy: penicillamine and vitamin E. Muscle Nerve. 1988 Nov; 11(11):1164-8.
    View in: PubMed
  55. Mendell JR, Province MA, Moxley RT, Griggs RC, Brooke MH, Fenichel GM, Miller JP, Kaiser KK, King W, Robison J, et al. Clinical investigation of Duchenne muscular dystrophy. A methodology for therapeutic trials based on natural history controls. Arch Neurol. 1987 Aug; 44(8):808-11.
    View in: PubMed
  56. Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley RT, Miller JP, Kaiser KK, Florence JM, Pandya S, Signore L, et al. Clinical investigation of Duchenne muscular dystrophy. Interesting results in a trial of prednisone. Arch Neurol. 1987 Aug; 44(8):812-7.
    View in: PubMed
  57. Moxley RT, Brooke MH, Fenichel GM, Mendell JR, Griggs RC, Miller JP, Province MA, Patterson V. Clinical investigation in Duchenne dystrophy. VI. Double-blind controlled trial of nifedipine. Muscle Nerve. 1987 Jan; 10(1):22-33.
    View in: PubMed
  58. Pandya S, Florence JM, King WM, Robison JD, Oxman M, Province MA. Reliability of goniometric measurements in patients with Duchenne muscular dystrophy. Phys Ther. 1985 Sep; 65(9):1339-42.
    View in: PubMed
  59. Mendell JR, Griggs RC, Moxley RT, Fenichel GM, Brooke MH, Miller JP, Province MA, Dodson WE. Clinical investigation in Duchenne muscular dystrophy: IV. Double-blind controlled trial of leucine. Muscle Nerve. 1984 Sep; 7(7):535-41.
    View in: PubMed
  60. Florence JM, Pandya S, King WM, Robison JD, Signore LC, Wentzell M, Province MA. Clinical trials in Duchenne dystrophy. Standardization and reliability of evaluation procedures. Phys Ther. 1984 Jan; 64(1):41-5.
    View in: PubMed
  61. Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley R, Miller JP, Province MA. Clinical investigation in Duchenne dystrophy: 2. Determination of the "power" of therapeutic trials based on the natural history. Muscle Nerve. 1983 Feb; 6(2):91-103.
    View in: PubMed
  62. Brooke MH, Griggs RC, Mendell JR, Fenichel GM, Shumate JB, Pellegrino RJ. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun; 4(3):186-97.
    View in: PubMed
  63. Griggs RC, Pandya S, Moxley RT, Forbes G, VanDyke DH, Pearce FJ. Treatment of myopathic carnitine deficiency: quantitation of response to prednisone and carnitine. Trans Am Neurol Assoc. 1981; 106:199-202.
    View in: PubMed

Visualizations


Pandya's Networks

Concepts
_
Co-Authors
_
Similar People
_
Same Department